Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain
Lazarus, Jeffrey V. (Hospital Clínic i Provincial de Barcelona)
Villota-Rivas, Marcela (Hospital Clínic i Provincial de Barcelona)
Ryan, Pablo (Hospital Universitario Infanta Leonor)
Buti, Maria (Hospital Universitari Vall d'Hebron)
Grau-López, Lara (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Cuevas, Guillermo (Hospital Universitario Infanta Leonor)
Espada, José Luis (Harm reduction Unit "SMASD" (Madrid))
Morón, William (Harm reduction Unit "SMASD" (Madrid))
Palma-Álvarez, Raul Felipe (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Feld, Jordan J. (University Health Network (Toronto, Canadà))
Valencia, Jorge (University Health Network (Toronto, Canadà))

Date:	2023
Abstract:	COVID-19 has hindered hepatitis C virus (HCV) and HIV screening, particularly in marginalised groups, who have some of the highest rates of these conditions and lowest rates of COVID-19 vaccination. We assessed the acceptability of combining HCV testing with COVID-19 vaccination in a centre for addiction services (CAS) in Barcelona and a mobile testing unit (MTU) in Madrid, Spain. From 28/09/2021 to 30/06/2022, 187 adults from marginalised populations were offered HCV antibody (Ab) testing along with COVID-19 vaccination. If HCV Ab+, they were tested for HCV-RNA. MTU participants were also screened for HIV. HCV-RNA+ and HIV+ participants were offered treatment. Data were analysed descriptively. Findings show how of the 86 CAS participants: 80 (93%) had been previously vaccinated for COVID-19, of whom 72 (90%) had the full first round schedule; none had a COVID-19 vaccine booster and all received a COVID - 19 vaccine; 54 (62. 8%) were tested for HCV Ab, of whom 17 (31. 5%) were positive, of whom all were tested for HCV-RNA and none were positive. Of the 101 MTU participants: none had been vaccinated for COVID-19 and all received a COVID-19 vaccine; all were tested for HCV Ab and HIV and 15 (14. 9%) and 9 (8. 9%) were positive, respectively; of those HCV Ab+, 9 (60%) were HCV-RNA+, of whom 8 (88. 9%) have started treatment; 5 (55. 6%) of those HIV+ had abandoned antiretroviral therapy, of whom 3 (60%) have re-started it. The intervention was accepted by 54 (62. 8%) CAS participants and all MTU participants and can be used in marginalised communities. The COVID-19 pandemic has reduced the numbers of people being screened to determine whether they are infected with the hepatitis C virus (HCV) or HIV. This is particularly the case for marginalised populations, which include people with substance use disorders (e. g. , injecting drug use), those who are experiencing homelessness, and those with mental health disorders. This study explored whether these populations were willing to be tested for HCV after receiving a COVID-19 vaccination in a centre for addiction services in Barcelona and a mobile testing unit (MTU) in Madrid, Spain. Those attending the MTU were also screened for HIV. Most participants were both vaccinated and tested for HCV and HIV, as applicable, when offered. Applying this approach more widely could improve healthcare reach among marginalised populations. Lazarus et al. offered hepatitis C virus (HCV) and HIV screening, alongside COVID-19 vaccination, to adults from marginalised populations. The combined intervention was accepted by over half of participants, identifying those who needed, and were offered, COVID-19 vaccination and HCV and HIV treatment.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Public health ; Hepatitis C ; HIV infections ; Health services
Published in:	Communications Medicine, Vol. 3 (may 2023) , ISSN 2730-664X

DOI: 10.1038/s43856-023-00292-y
PMID: 37173456

11 p, 1.1 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles